TrialNature communications2022

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.

Nawal Al Kaabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.